Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy

J Infect Dis. 2001 Nov 1;184(9):1197-201. doi: 10.1086/323805. Epub 2001 Oct 12.

Abstract

Subcutaneous adipocyte apoptosis occurs in lipotrophic areas of patients with highly active antiretroviral therapy (HAART)-associated lipodystrophy. Fourteen patients with HAART-associated lipodystrophy had 2 subcutaneous biopsies for evidence of adipocyte apoptosis, the second after a randomized change to nevirapine (n=8) or after remaining on a regimen of indinavir-based HAART (n=6). Apoptosis was assessed by the terminal deoxynucleotidyl transferase dUTP-digoxigenin nick end-labeling method. Patients who were switched to nevirapine had a significant decrease in insulinemia and a significant increase in the glucose:insulin ratio. Overall, subcutaneous adipocyte apoptosis increased in 3 patients who were switched to nevirapine and in 3 who continued to receive indinavir but decreased in 2 patients switched to nevirapine and another 2 who continued to receive indinavir. Subcutaneous adipocyte apoptosis continues to occur in lipotrophic areas of patients with HAART-associated lipodystrophy despite switching from indinavir to nevirapine, suggesting that such a strategy will be useless for reversal of lipoatrophy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes / pathology*
  • Adult
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Apoptosis
  • Blood Glucose
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • Humans
  • In Situ Nick-End Labeling
  • Indinavir / adverse effects
  • Indinavir / therapeutic use
  • Insulin / blood*
  • Lipodystrophy / chemically induced*
  • Lipodystrophy / pathology
  • Male
  • Middle Aged
  • Nevirapine / adverse effects
  • Nevirapine / therapeutic use*
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / therapeutic use

Substances

  • Anti-HIV Agents
  • Blood Glucose
  • Insulin
  • Reverse Transcriptase Inhibitors
  • Indinavir
  • Nevirapine